Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

Clinical Trials

Please use the search below. See our frequently asked questions regarding clinical trials. 

Showing 1 - 10 of 160

Fairfax Stem Cell Transplant Program: Autologous Transplantation Recipient and Allogeneic Related Donor Data Collection

As a transplant program we are required to collect data to document the quality of our program, maintain accreditation with national and international societies, and to enhance our understanding of stem cell transplant and the response patients have to transplant. Our transplant center sends transplant related information to US Oncology (network that we are affiliated with), the Inova Fairfax Hospital Stem Cell Transplant team, and the Center for International Blood and Bone Marrow Transplant Research (CIBMTR). For those patients having a matched unrelated donor transplant, information will be sent to the National Marrow Donor Program (NMDP). On occasion we supply statistical information to federal and state agencies and insurance companies without specific reference to individual patients.

TRUST (Treatment Results of Uterine Sparing Technologies) USA Study

Women 18 or older with untreated fibroids who wish to receive treatment and avoid hysterectomy may be eligible to receive treatment through the study.

Participants will be randomly assigned to receive one of the three treatments and will subsequently be required to attend the pre- and post-operative appointments that are standard to the assigned procedure.

All three procedures – myomectomy, UAE, and RFVTA – have been cleared by the Food and Drug Administration for commercial use. All three methods are currently being utilized by US gynecologists for treating fibroids.

Vaginal Tactile Imaging in Assessment of Pelvic Floor Conditions

The study is designed to assess the elasticity of pelvic floor muscles in women with varying degree of pelvic organ prolapse.


The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.

Showing 1 - 10 of 160